Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

NCT01885208 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

813

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: semaglutide
DRUG: exenatide

Sponsor

Novo Nordisk A/S